International audienceEffective treatment for pancreatic cancer remains challenging, particularly the treatment of pancreatic ductal adenocarcinoma (PDAC), which makes up more than 95% of all pancreatic cancers. Late diagnosis and failure of chemotherapy and radiotherapy are all too common, and many patients die soon after diagnosis. Here, we make the case for the increased use of molecular imaging in PDAC preclinical research and in patient management
Pancreatic ductal adenocarcinoma carries a dismal prognosis. Both chemotherapy and targeted therapie...
ABSTRACT: Development of novel imaging probes for cancer diagnostics remains critical for early dete...
Pancreatic ductal adenocarcinoma usually has a very poor outcome. The majority of patients present l...
International audienceEffective treatment for pancreatic cancer remains challenging, particularly th...
Effective treatment for pancreatic cancer remains challenging, particularly the treatment of pancrea...
Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer characterized by multiple molecular alter...
Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis. To improve outcomes, there is a crit...
There is now compelling evidence to suggest that the molecular heterogeneity of histologically indis...
Pancreatic adenocarcinoma is one of the deadliest human malignancies. Early detection is difficult a...
Pancreatic ductal adenocarcinoma (PDAC), accounting for 90–95% of all pancreatic tumors, is a highly...
Despite improvements in surgical techniques and adjuvant chemotherapy, the overall mortality rates i...
Background: Novel technology has enabled researchers to better characterize pancreatic cancers at th...
For years, pancreatic cancer had a dismal prognosis with a long term survival of around 5%...
Pancreatic Ductal Adenocarcinoma (PDAC) constitutes a leading cause of cancer death globally. Its mo...
Pancreatic cancer, one of the most lethal malignancies, is increasing in incidence. While survival r...
Pancreatic ductal adenocarcinoma carries a dismal prognosis. Both chemotherapy and targeted therapie...
ABSTRACT: Development of novel imaging probes for cancer diagnostics remains critical for early dete...
Pancreatic ductal adenocarcinoma usually has a very poor outcome. The majority of patients present l...
International audienceEffective treatment for pancreatic cancer remains challenging, particularly th...
Effective treatment for pancreatic cancer remains challenging, particularly the treatment of pancrea...
Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer characterized by multiple molecular alter...
Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis. To improve outcomes, there is a crit...
There is now compelling evidence to suggest that the molecular heterogeneity of histologically indis...
Pancreatic adenocarcinoma is one of the deadliest human malignancies. Early detection is difficult a...
Pancreatic ductal adenocarcinoma (PDAC), accounting for 90–95% of all pancreatic tumors, is a highly...
Despite improvements in surgical techniques and adjuvant chemotherapy, the overall mortality rates i...
Background: Novel technology has enabled researchers to better characterize pancreatic cancers at th...
For years, pancreatic cancer had a dismal prognosis with a long term survival of around 5%...
Pancreatic Ductal Adenocarcinoma (PDAC) constitutes a leading cause of cancer death globally. Its mo...
Pancreatic cancer, one of the most lethal malignancies, is increasing in incidence. While survival r...
Pancreatic ductal adenocarcinoma carries a dismal prognosis. Both chemotherapy and targeted therapie...
ABSTRACT: Development of novel imaging probes for cancer diagnostics remains critical for early dete...
Pancreatic ductal adenocarcinoma usually has a very poor outcome. The majority of patients present l...